Fusion Polypeptide with IMiD-Responsive Degradation Domain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Therapeutic proteins often face challenges with side effects such as loss of efficacy or toxicity, and there is a need to modulate their expression levels effectively.
Innovation Solution
A fusion polypeptide comprising a degradation polypeptide and a heterologous polypeptide, where the degradation polypeptide has a specific amino acid sequence that interacts with immunomodulatory imide drugs (IMiDs) to regulate the expression and degradation of the fusion polypeptide, specifically decreasing its expression in the presence of IMiDs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic proteins are used to treat diseases, then disease treatment efficacy is improved, but side effects such as toxicity and loss of drug efficacy occur
Solution Approach 1:
The patent applies dynamics by creating a fusion polypeptide with a degradation domain that enables dynamic regulation of protein expression levels. The degradation domain allows the therapeutic protein to be selectively degraded when bound to IMiD drugs, transforming the static protein expression into a dynamic, controllable process that can adapt to treatment needs and reduce toxicity.
Solution Approach 2:
The patent changes the parameter of protein expression level by incorporating a degradation domain that responds to IMiD drug binding. This causes the expression level of the fusion polypeptide to decrease significantly (by at least 40-99%) when IMiD is present, allowing modulation of therapeutic protein levels to balance efficacy and reduce side effects.
2Reliability
If protein expression levels are increased to enhance therapeutic effect, then treatment efficacy is improved, but toxicity and adverse reactions increase
Solution Approach 1:
The patent implements feedback by creating a system where the degradation domain monitors and responds to IMiD drug presence. When IMiD binds to the degradation domain, it triggers a feedback loop that activates protein degradation, thereby reducing toxic protein accumulation while maintaining therapeutic effect through controlled expression modulation.
Solution Approach 2:
The patent extracts the harmful aspect by separating the therapeutic function from the toxic accumulation through the degradation domain. The degradation domain acts as a selective removal mechanism that extracts or removes the therapeutic protein from circulation when toxicity is detected, while preserving the protein's therapeutic activity when needed.
3Adaptability or versatility
If a fusion polypeptide is designed with a degradation domain to enable controlled degradation, then expression level modulation is achieved, but protein stability is reduced
Solution Approach 1:
The patent applies segmentation by dividing the fusion polypeptide into distinct functional segments: a stable therapeutic protein portion and a separate degradation domain portion. This segmentation allows the therapeutic protein to maintain its structural stability while the degradation domain provides independent control over protein levels, resolving the conflict between stability and modularity.
Solution Approach 2:
The patent uses an intermediary mechanism where the degradation domain acts as a mediator between the therapeutic protein and the degradation machinery. This intermediary component enables controlled protein degradation without directly compromising the stability of the therapeutic protein itself, as the degradation domain serves as a regulatory bridge rather than a direct destabilizing force.
Data Source
AI summary
The invention provides compositions including a fusion polypeptide and methods for making a fusion polypeptide that includes a degradation polypeptide and a heterologous polypeptide of interest.